Centiva Capital LP Invests $59,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Posted by Defense World Staff on Feb 27th, 2023

Centiva Capital LP bought a new stake in Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 14,000 shares of the biotechnology company’s stock, valued at approximately $59,000.

Several other hedge funds have also bought and sold shares of the stock. Commonwealth Equity Services LLC raised its position in shares of Heron Therapeutics by 43.4% during the 2nd quarter. Commonwealth Equity Services LLC now owns 16,522 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 5,000 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in Heron Therapeutics during the first quarter valued at about $48,000. Captrust Financial Advisors lifted its stake in Heron Therapeutics by 1,539.5% during the second quarter. Captrust Financial Advisors now owns 17,789 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 16,704 shares during the last quarter. Bridgefront Capital LLC purchased a new position in shares of Heron Therapeutics in the 1st quarter worth about $60,000. Finally, Quent Capital LLC bought a new position in shares of Heron Therapeutics during the 3rd quarter valued at about $68,000.

Heron Therapeutics Price Performance

HRTX opened at $2.28 on Monday. The company has a debt-to-equity ratio of 6.65, a current ratio of 2.38 and a quick ratio of 1.83. The stock’s 50 day simple moving average is $2.71 and its 200 day simple moving average is $3.43. The firm has a market cap of $271.07 million, a price-to-earnings ratio of -1.09 and a beta of 0.85. Heron Therapeutics, Inc. has a 1 year low of $2.19 and a 1 year high of $7.62.

Analyst Ratings Changes

Several analysts have issued reports on HRTX shares. Needham & Company LLC cut their target price on Heron Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, November 9th. StockNews.com raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 17th. Finally, Evercore ISI decreased their target price on shares of Heron Therapeutics to $15.00 in a research report on Tuesday, November 15th.

About Heron Therapeutics

(Get Rating)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.